XAIR vs XTLB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
XAIR exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and an operating margin of -300.64%. While the company shows impressive top-line revenue growth (>100% YoY), it is failing to convert this into any meaningful profitability, with gross margins nearly flat at 1.82%. The massive disconnect between the current price ($0.55) and the analyst target price ($8.67) suggests a speculative bubble or outdated analyst models that ignore the company's deteriorating fundamental health. With a 5-year price collapse of 99.5%, the stock is in a clear long-term bearish trend.
XTLB exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a complete lack of positive fundamental momentum. The company suffers from catastrophic profitability metrics, including an operating margin of -853.58% and a negative gross margin of -232.85%, indicating a fundamentally broken cost structure. Liquidity is critical with a current ratio of 0.70 and a quick ratio of 0.46, suggesting an inability to meet short-term obligations. Combined with a 0/100 technical trend and an 81.5% decline over five years, the stock presents an extremely high-risk profile.
Compare Another Pair
Related Comparisons
XAIR vs XTLB: Head-to-Head Comparison
This page compares Beyond Air, Inc. (XAIR) and XTL Biopharmaceuticals Ltd. (XTLB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.